ASBP Aspire Biopharma Holdings, Inc.
Stock · NasdaqCM · United States · Consumer Cyclical · US7389203057
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Aspire Biopharma Holdings, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:42. Information, not advice.
Results
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 6.2K | — | -24.5M | -394,725.1% | -491.40 | -1,338.3% | -4.9M |
| 2024 | 0 | — | -1.3M | — | -34.17 | -129.3% | -265.2K |
| 2023 | 0 | — | 4.5M | — | 116.44 | +847.6% | 11.1K |
| 2022 | 0 | — | -597.1K | — | -15.57 | — | -5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 03 Jan 2023 – 06 Jan 2023 | 412.00 | 412.80 | 412.00 | 412.80 | +0.19% | 143 | |
| 27 Dec 2022 – 30 Dec 2022 | 412.40 | 412.80 | 412.00 | 412.00 | -0.10% | 136 | |
| 19 Dec 2022 – 23 Dec 2022 | 411.40 | 412.40 | 411.40 | 412.40 | +0.10% | 2,986 | |
| 12 Dec 2022 – 16 Dec 2022 | 410.80 | 412.00 | 410.80 | 412.00 | +0.39% | 17,787 | |
| 05 Dec 2022 – 09 Dec 2022 | 410.00 | 410.40 | 410.00 | 410.40 | +0.10% | 4,528 | |
| 28 Nov 2022 – 02 Dec 2022 | 409.20 | 410.00 | 409.20 | 410.00 | +0.15% | 9,419 | |
| 21 Nov 2022 – 25 Nov 2022 | 409.00 | 409.40 | 409.00 | 409.40 | +0.10% | 76 | |
| 14 Nov 2022 – 18 Nov 2022 | 408.20 | 409.92 | 408.20 | 409.00 | +0.20% | 2,774 | |
| 07 Nov 2022 – 11 Nov 2022 | 407.60 | 408.20 | 407.60 | 408.20 | +0.20% | 796 | |
| 31 Oct 2022 – 04 Nov 2022 | 406.80 | 407.40 | 406.80 | 407.40 | +0.10% | 4,188 | |
| 24 Oct 2022 – 28 Oct 2022 | 406.00 | 407.00 | 406.00 | 407.00 | +0.15% | 6,850 | |
| 17 Oct 2022 – 21 Oct 2022 | 404.40 | 406.40 | 404.00 | 406.40 | +0.59% | 1,117 | |
| 10 Oct 2022 – 14 Oct 2022 | 403.80 | 404.40 | 403.80 | 404.00 | 0.00% | 136 | |
| 03 Oct 2022 – 07 Oct 2022 | 404.80 | 422.00 | 403.60 | 404.00 | -0.39% | 1,004 | |
| 26 Sep 2022 – 30 Sep 2022 | 404.40 | 405.60 | 404.00 | 405.60 | +0.30% | 6,162 | |
| 19 Sep 2022 – 23 Sep 2022 | 404.00 | 424.00 | 403.60 | 404.40 | +0.10% | 14,299 | |
| 12 Sep 2022 – 16 Sep 2022 | 403.20 | 404.00 | 403.04 | 404.00 | +0.15% | 1,833 | |
| 06 Sep 2022 – 09 Sep 2022 | 403.60 | 404.00 | 403.00 | 403.40 | +0.05% | 189 | |
| 29 Aug 2022 – 02 Sep 2022 | 403.20 | 404.00 | 402.40 | 403.20 | +0.10% | 701 | |
| 22 Aug 2022 – 26 Aug 2022 | 401.60 | 403.60 | 401.60 | 402.80 | +0.20% | 22,829 | |
| 15 Aug 2022 – 19 Aug 2022 | 402.00 | 402.40 | 401.20 | 402.00 | -0.10% | 10,401 | |
| 08 Aug 2022 – 12 Aug 2022 | 401.60 | 402.40 | 401.60 | 402.40 | +0.10% | 5,288 | |
| 01 Aug 2022 – 05 Aug 2022 | 400.40 | 402.00 | 400.40 | 402.00 | +0.25% | 3,163 | |
| 25 Jul 2022 – 29 Jul 2022 | 400.00 | 401.00 | 400.00 | 401.00 | -0.25% | 22,511 | |
| 18 Jul 2022 – 22 Jul 2022 | 399.60 | 402.00 | 399.20 | 402.00 | +0.60% | 798 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal (opens in a new tab) Benzinga · 11 Aug 2026 03:31
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 6.76 USD
- Market cap
- 11.3M
- Exchange
- NasdaqCM
- Country
- United States
- Sector
- Consumer Cyclical
- Industry
- Auto Parts
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 10.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 3.5 / 10 No figures for this part: it counts as a cautious 35%. | — |
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -2.3× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 60% of the figures (grade C). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Price / book | 0.89× | Good | 1.89× |
| Price / sales | 116.19× | Weak | 1.01× |
| Free cash flow yield | 65.5% | Good | 4.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | -25% | Weak | 39.1% |
| Operating margin | -3,880.6% | Weak | 8% |
| Net margin | 0% | Weak | 5.1% |
| Return on equity | -1,032.1% | Weak | 12.9% |
| Return on assets | 60.6% | Good | 5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -0.81× | Good | 0.78× |
| Interest cover | -2.27× | Weak | 4.85× |
| Current ratio | 7.99× | Good | 1.38× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ASBP and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.